# Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

> **NCT03864419** · PHASE1 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Burkitt Lymphoma
- KSHV-associated Multicentric Castleman Disease
- Diffuse Large B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Rituximab and Hyaluronidase Human
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Methotrexate
- **DRUG:** Doxorubicin
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Prednisone
- **DRUG:** Etoposide
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT03864419
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-24
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Closed per SRC Low Accrual Policy
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03864419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03864419, "Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03864419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*